85 related articles for article (PubMed ID: 8444677)
1. RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria.
Pfaller MA; Barry AL; Fuchs PC
J Antimicrob Chemother; 1993 Jan; 31(1):81-8. PubMed ID: 8444677
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of Ro 23-9424, a dual-acting cephalosporin-quinolone antimicrobial agent.
Qadri SM; Ueno Y; Saldin H; Cunha BA
J Clin Pharmacol; 1993 Oct; 33(10):923-8. PubMed ID: 8227462
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.
Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1989 Jun; 33(6):944-50. PubMed ID: 2504106
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
Jones RN; Sanchez ML
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
[TBL] [Abstract][Full Text] [Related]
5. RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
Fuchs PC; Jones RN; Barry AL; Ayers LW; Gavan TL; Gerlach EH; Thornsberry C
Diagn Microbiol Infect Dis; 1987 May; 7(1):29-35. PubMed ID: 3121241
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.
Rolston KV; Nguyen HT; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1992 Apr; 36(4):879-82. PubMed ID: 1503453
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
Gu JW; Neu HC
Antimicrob Agents Chemother; 1990 Feb; 34(2):189-95. PubMed ID: 2327765
[TBL] [Abstract][Full Text] [Related]
8. Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.
Chapman JS; Bertasso A; Cummings LM; Georgopapadakou NH
Antimicrob Agents Chemother; 1995 Feb; 39(2):564-6. PubMed ID: 7726536
[TBL] [Abstract][Full Text] [Related]
9. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
Qadri SM; Ueno Y; Ayub A
Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.
Beskid G; Fallat V; Lipschitz ER; McGarry DH; Cleeland R; Chan K; Keith DD; Unowsky J
Antimicrob Agents Chemother; 1989 Jul; 33(7):1072-7. PubMed ID: 2782857
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of Ro 24-6778, a covalent bonding of desmethylfleroxacin and desacetylcefotaxime.
Jones RN
Diagn Microbiol Infect Dis; 1990; 13(3):253-9. PubMed ID: 2116952
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Beskid G; Siebelist J; McGarry CM; Cleeland R; Chan K; Keith DD
Chemotherapy; 1990; 36(2):109-16. PubMed ID: 2107064
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399.
Pfaller MA; Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1993 Apr; 37(4):893-5. PubMed ID: 8494387
[TBL] [Abstract][Full Text] [Related]
14. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.
Pace J; Bertasso A; Georgopapadakou NH
Antimicrob Agents Chemother; 1991 May; 35(5):910-5. PubMed ID: 1649574
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
Spangler SK; Jacobs MR; Pankuch GA; Appelbaum PC
J Antimicrob Chemother; 1993 Feb; 31(2):273-80. PubMed ID: 8463172
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of the dual-action cephalosporin Ro 23-9424.
Georgopapadakou NH; Bertasso A; Chan KK; Chapman JS; Cleeland R; Cummings LM; Dix BA; Keith DD
Antimicrob Agents Chemother; 1989 Jul; 33(7):1067-71. PubMed ID: 2675755
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.
Edelstein PH; Edelstein MA
Antimicrob Agents Chemother; 1992 Nov; 36(11):2559-61. PubMed ID: 1489206
[TBL] [Abstract][Full Text] [Related]
18. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents.
Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC
Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
20. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
